Matrix Metallopeptidase 3 Polymorphisms: Emerging Genetic Markers in Human Breast Cancer Metastasis

Overview

Journal J Breast Cancer

Date 2020 Mar 7

PMID 32140265

Citations 18

Authors

Shafinah Ahmad Suhaimi

Soon Choy Chan

Rozita Rosli

Affiliations

Soon will be listed here.

Abstract

Matrix metallopeptidase 3 or , is a zinc-dependent proteolytic enzyme that is involved in various physiological processes via modification of the extracellular matrix. In particular, its over-expression has been associated with cancer metastasis and tumor growth in various cancers including breast cancer. gene expression is regulated by several factors such as DNA polymorphisms which also serve as risk factors for breast cancer. As such, DNA polymorphisms of have the potential to be utilized as genetic biomarkers for prediction and prognosis of metastatic breast cancer. Presently, genome-wide association studies of gene polymorphisms which are associated with breast cancer risk and patient survival in a variety of populations are reviewed. In order to understand the potential role of polymorphisms as genetic markers for breast cancer metastasis, the domain structure of , the regulation of its expression and its role in breast cancer metastasis are also briefly discussed in this review. The emergence of gene polymorphisms as prognostic biomarker candidates for breast cancer metastasis may contribute towards improving targeted therapies and categorization of breast cancer cases in order to provide a better and more accurate prognosis.

Citing Articles

Development and validation of a biomarker-based prediction model for metastasis in patients with colorectal cancer: Application of machine learning algorithms.

Ayubi E, Farashi S, Tapak L, Afshar S Heliyon. 2025; 11(1):e41443.

PMID: 39839508 PMC: 11748706. DOI: 10.1016/j.heliyon.2024.e41443.

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Szczygielski O, Dabrowska E, Niemyjska S, Przylipiak A, Zajkowska M Int J Mol Sci. 2025; 25(24.

PMID: 39769318 PMC: 11676509. DOI: 10.3390/ijms252413558.

Tenascin-C-Matrix Metalloproteinase-3 Phenotype and the Risk of Tendinopathy in High-Performance Athletes: A Case-Control Study.

Lopes L, Amaral M, Goes R, Tavares V, Dias F, Medeiros R Diagnostics (Basel). 2024; 14(22).

PMID: 39594135 PMC: 11592874. DOI: 10.3390/diagnostics14222469.

Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies.

Pomella S, Melaiu O, Cifaldi L, Bei R, Gargari M, Campanella V Int J Mol Sci. 2024; 25(16).

PMID: 39201614 PMC: 11354375. DOI: 10.3390/ijms25168929.

MMP-3 mediates copper oxide nanoparticle-induced pulmonary inflammation and fibrosis.

Zhang Y, Zhang Z, Mo Y, Zhang Y, Yuan J, Zhang Q J Nanobiotechnology. 2024; 22(1):428.

PMID: 39030581 PMC: 11264740. DOI: 10.1186/s12951-024-02707-x.

References

Sipos F, Germann T, Wichmann B, Galamb O, Spisak S, Krenacs T . MMP3 and CXCL1 are potent stromal protein markers of dysplasia-carcinoma transition in sporadic colorectal cancer. Eur J Cancer Prev. 2014; 23(5):336-43. DOI: 10.1097/CEJ.0000000000000058. View

Munhoz F, Godoy-Santos A, Santos M . MMP-3 polymorphism: Genetic marker in pathological processes (Review). Mol Med Rep. 2011; 3(5):735-40. DOI: 10.3892/mmr.2010.340. View

Ghilardi G, Biondi M, Caputo M, Leviti S, DeMonti M, Guagnellini E . A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002; 8(12):3820-3. View

Sternlicht M, Lochter A, Sympson C, Huey B, Rougier J, Gray J . The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999; 98(2):137-46. PMC: 2853255. DOI: 10.1016/s0092-8674(00)81009-0. View

Nabeshima K, Inoue T, Shimao Y, Sameshima T . Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002; 52(4):255-64. DOI: 10.1046/j.1440-1827.2002.01343.x. View

Lei H, Zaloudik J, Vorechovsky I . Lack of association of the -1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem. 2002; 48(5):798-9. View

Krishnaveni D, Bhayal A, Shravan K, Jyothy A, Pratibha N, Venkateshwari A . Heterozygosity of stromelysin-1 (rs3025058) promoter polymorphism is associated with gastric cancer. Indian J Cancer. 2016; 52(2):251-4. DOI: 10.4103/0019-509X.175806. View

Decock J, Thirkettle S, Wagstaff L, Edwards D . Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med. 2011; 15(6):1254-65. PMC: 4373327. DOI: 10.1111/j.1582-4934.2011.01302.x. View

Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries S, Henney A . Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996; 271(22):13055-60. DOI: 10.1074/jbc.271.22.13055. View

10.

Hughes S, Agbaje O, Bowen R, Holliday D, Shaw J, Duffy S . Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res. 2007; 13(22 Pt 1):6673-80. DOI: 10.1158/1078-0432.CCR-07-0884. View

11.

Holliday D, Hughes S, Shaw J, Walker R, Jones J . Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res. 2007; 9(5):R67. PMC: 2242664. DOI: 10.1186/bcr1775. View

12.

Shevchenko A, Konenkov V, Garbukov E, Stakheeva M . [Associating of polymorphism in the promoter regions of genes of metalloproteinase (MMP2, MMP3, MMP9) with options of the clinical course of breast cancer in Russian women]. Vopr Onkol. 2015; 60(5):630-5. View

13.

Beeghly-Fadiel A, Cai Q, Lu W, Long J, Gao Y, Shu X . No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1324-7. PMC: 2701308. DOI: 10.1158/1055-9965.EPI-09-0046. View

14.

Banik D, Netherby C, Bogner P, Abrams S . MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction. Oncotarget. 2015; 6(17):15164-79. PMC: 4558143. DOI: 10.18632/oncotarget.3897. View

15.

Srivastava P, Kapoor R, Mittal R . Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. Gene. 2013; 530(2):273-7. DOI: 10.1016/j.gene.2013.06.087. View

16.

Mehner C, Miller E, Nassar A, Bamlet W, Radisky E, Radisky D . Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer. 2016; 6(11-12):480-9. PMC: 4701227. DOI: 10.18632/genesandcancer.90. View

17.

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

18.

Rebbeck T, Ambrosone C, Bell D, Chanock S, Hayes R, Kadlubar F . SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2004; 13(5):681-7. View

19.

Duffy M, Maguire T, Hill A, McDermott E, OHiggins N . Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2001; 2(4):252-7. PMC: 138784. DOI: 10.1186/bcr65. View

20.

Yan C, Boyd D . Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2006; 211(1):19-26. DOI: 10.1002/jcp.20948. View